Physician profile
Debra S Davis
NPI 1508933748
$11,804.73
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,744 · 2020: $1,953 · 2021: $2,014 · 2022: $1,963 · 2023: $1,904 · 2024: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,035.27 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,540.98 | 2019-2024 | Mounjaro, Jardiance, Humulin |
| Abbott Laboratories | $1,031.92 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $1,027.35 | 2019-2022 | |
| Abbvie INC. | $672.49 | 2019-2024 | Ubrelvy, Vraylar, Synthroid |
| Dexcom, INC. | $661.33 | 2019-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $553.06 | 2019-2023 | Korlym |
| Amarin Pharma, INC. | $409.92 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $338.92 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $327.80 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $326.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $284.41 | 2020-2022 | |
| Astellas Pharma US INC | $272.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.61 | 2022-2024 | Jardiance |
| Amgen INC. | $236.56 | 2019-2024 | Evenity, Prolia, Repatha |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.